Zydus Lifesciences Ltd on Tuesday reported a robust second-quarter performance for FY26, with consolidated net profit rising 39% year-on-year to ₹1,259 crore, compared with ₹911 crore in the same period last year.
The growth was supported by healthy business momentum across geographies and a sharp rise in forex gains.
The company recorded a foreign exchange gain of ₹414 crore, compared with ₹45 crore in the previous year.
Research and development (R&D) expenditure stood at ₹482 crore, or 7.9% of revenue, reflecting continued investment in innovation and complex generics.
Revenue for the quarter climbed 17% year-on-year to ₹6,123 crore, led by strong performance in the company’s US and India formulations businesses.
Operating profitability improved significantly, with EBITDA surging 38% to ₹2,014 crore, while margins expanded to 32.9% from 27.9% a year earlier, aided by a richer product mix and disciplined cost control.
“Our strong performance this quarter reaffirms the power of our diversified business model and execution capabilities across geographies and verticals,” said Dr. Sharvil Patel, Managing Director of Zydus Lifesciences.
“We delivered robust revenue growth and industry-leading profitability, aided by consistent outperformance in our US and India formulations businesses, sustained international growth, and strategic acquisitions in Wellness and MedTech,” he added.
Post earnings, shares of Zydus Lifesciences climbed to an intraday high of ₹998 before easing to ₹953.40 on the NSE, down 1.9% as of 1:45 PM.
